BIOMAT Database Logo BIOMAT Database Logo

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. 2022

Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in the molecular relapse after TKIs discontinuation. Aberrant DNA hypermethylation contributes to low TKIs sensitivity and the persistence of LSCs in CML. DNMT1 is a key regulator of hematopoietic stem cells, suggesting that aberrant DNA hypermethylation targeting DNMT1 represents a potential therapeutic target for CML. We investigated the efficacy of OR-2100 (OR21), the first orally available single-compound prodrug of decitabine. OR21 exhibited anti-tumor effects as a monotherapy, and in combination therapy it increased TKI-induced apoptosis and induction of tumor suppressor genes including PTPN6 encoding SHP-1 in CML cells. OR21 in combination with imatinib significantly suppressed tumor growth in a xenotransplant model. OR21 and combination therapy decreased the abundance of LSCs and inhibited engraftment in a BCR-ABL1-transduced mouse model. These results demonstrate that targeting DNMT1 using OR21 exerts anti-tumor effects and impairs LSCs in CML. Therefore, combination treatment of TKIs and OR21 represents a promising treatment strategy in CML.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076123 DNA (Cytosine-5-)-Methyltransferase 1 A DNA (cytosine-5-)-methyltransferase that contains a central CxxC type zinc finger motif. It binds poly(ADP)-ribose and its expression is regulated by POLY (ADP-RIBOSE) POLYMERASE-1. DNMT1 methylates CpG residues, with a preference for hemimethylated DNA, and associates with DNA replication sites in S PHASE to maintain the methylation pattern in the newly synthesized strand, which is essential for EPIGENETIC PROCESSES. It also associates with CHROMATIN during G2 PHASE and MITOSIS to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development; mutations in the DNMT1 gene are associated with HEREDITARY SENSORY NEUROPATHY TYPE 1 class E. DNMT1 Enzyme,Enzyme, DNMT1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
[Tyrosine kinase inhibitors and leukemic stem cells in chronic myeloid leukemia].
July 2011, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
June 2010, Haematologica,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
October 2020, Experimental hematology,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
July 2019, BMC cancer,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
[Chronic myeloid leukemia and tyrosine kinase inhibitors].
September 2001, La Revue de medecine interne,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Tyrosine kinase inhibitors in chronic myeloid leukemia.
January 1999, The cancer journal from Scientific American,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
[Tyrosine kinase inhibitors for chronic myeloid leukemia].
December 2023, La Revue du praticien,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.
June 2022, Science translational medicine,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.
February 2023, Cancers,
Kazuharu Kamachi, and Hiroshi Ureshino, and Tatsuro Watanabe, and Nao Yoshida, and Yuta Yamamoto, and Yuki Kurahashi, and Yuki Fukuda-Kurahashi, and Yoshihiro Hayashi, and Hideyo Hirai, and Satoshi Yamashita, and Toshikazu Ushijima, and Seiji Okada, and Shinya Kimura
Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
November 2005, Leukemia,
Copied contents to your clipboard!